Table 2

Typical age(s) at receipt of hepatitis B vaccine doses and change in % underimmunized at 24 months for the hepatitis B vaccine series, baseline vs. birth dose suspension cohorts, children enrolled in five large U.S. provider groups, October 1996 – December 1999

Modal Age in Months at Hepatitis B Vaccination*


Group

Exposure cohort

Dose 1

Dose 2

Dose 3

Predicted Absolute Change in % Underimmunized at 24 Months in the Suspension vs. Baseline Period

OR for Being Underimmunized at 24 Months in the Suspension vs. Baseline Period (95% CI)§


A

Baseline:

≤2

3–4

11–12

-2%

0.7 (0.4 – 1.3)

Suspension:

≤2

3–4

11–12

B

Baseline:

≤2

≤2

17–18

-5%

0.5 (0.2 – 0.9)

Suspension:

≤2

3–4

11–12

C

Baseline:

Birth

≤2

5–6

-3%

0.8 (0.7 – 0.9)

Suspension:

≤2

3–4

5–6

D

Baseline:

Birth

≤2

9–10

+6%

2.7 (1.7 – 4.4)

Suspension:

5–6

9–10

15–16

E

Baseline:

Birth

≤2

5–6

+9%

3.1 (2.3 – 4.2)

Suspension:

5–6

9–10

11–12


*Baseline cohort: Born between October 1996 – June 1999 (n = 67,835). Birth dose suspension cohort: Born between July – September 1999 (n = 6,401). Age at vaccination was grouped into the following categories: birth (0–7 days), ≤ 2 months (8 days – 2 months), 3–4 months, 5–6 months, 7–8 months, 9–10 months, 11–12 months, 13–14 months, 15–16 months, 17–18 months, 19–20 months, 21–24 months, and did not receive dose by 24 months. For each dose, the most common ages at vaccination were listed.

For each provider group, the predicted absolute difference was calculated comparing the % hepatitis B underimmunized at age 24 months among the July 1999 birth cohort as fitted from multivariate regression models adjusting for temporal trend versus the % underimmunized as extrapolated from baseline (i.e., absolute difference = [fitted % underimmunized]July1999 - [predicted % underimmunized]July1999).

p < 0.05.

§ ORs are from logistic regression models adjusted for temporal trend.

Lin et al. BMC Pediatrics 2006 6:31   doi:10.1186/1471-2431-6-31

Open Data